-
Mashup Score: 0Phase 3 Evaluation of Sigvotatug Vedotin Is Underway in Pretreated Nonsquamous NSCLC - 2 hour(s) ago
Sigvotatug vedotin is being compared with docetaxel in patients with pretreated NSCLC in the phase 3 Be6A Lung-01 study.
Source: www.onclive.comCategories: General Medicine NewsTweet
-
Mashup Score: 1Fox Chase Cancer Center and Temple Researchers Highlight Need For Molecular Testing in Diagnosing Two Types of Kidney Cancer - 3 hour(s) ago
Genetic testing could help determine differences between rare forms of kidney cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Fox Chase Cancer Center and Temple Researchers Highlight Need For Molecular Testing in Diagnosing Two Types of Kidney Cancer @FoxChaseCancer #KidneyCancer #kcsm https://t.co/52I6kLvWsh
-
-
Mashup Score: 2Anlotinib Plus Toripalimab Yields Antitumor Activity in Advanced Soft Tissue Sarcoma and Bone Sarcoma - 3 hour(s) ago
Treatment with the combination of anlotinib and toripalimab produced durable efficacy in soft tissue sarcoma and bone sarcoma.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Anlotinib Plus Toripalimab Yields Antitumor Activity in Advanced Soft Tissue Sarcoma and Bone Sarcoma #sarcoma #oncology https://t.co/LKxjdDr0Y7
-
-
Mashup Score: 5
CD19 t-haNK demonstrated complete responses in 2 patients with heavily pretreated Waldenstrom macroglobulinemia.
Source: www.onclive.comCategories: General Medicine NewsTweet-
CD19 t-haNK Leads to Complete Responses in Waldenstrom Macroglobulinemia #hematology #CART https://t.co/RY3c2GYxTr
-
-
Mashup Score: 3Health Canada Authorizes Perioperative Pembrolizumab in Resectable, Locally Advanced HNSCC - 6 hour(s) ago
Perioperative pembrolizumab has received the green light for use in combination with radiotherapy with or without cisplatin in PD-L1–positive HNSCC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Health Canada Authorizes Perioperative Pembrolizumab in Resectable, Locally Advanced HNSCC #oncology #HNSCC https://t.co/cnRVhhALJY
-
-
Mashup Score: 7
Real-world tucatinib-based regimens were effective in different lines for HER2-positive metastatic breast cancer, including after trastuzumab deruxtecan.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Real-World Data Support Tucatinib-Based Treatment in HER2+ Metastatic Breast Cancer #bcsm #oncology https://t.co/HkbyYFSAxX
-
-
Mashup Score: 1Encorafenib Triplet Could Address Poor Outcomes With Immunotherapy in BRAF V600–Mutant Melanoma With Brain Metastases - 8 hour(s) ago
Zeynep Eroglu, MD, discusses the potential PFS benefit with encorafenib plus binimetinib and nivolumab in BRAF V600–mutant melanoma with symptomatic brain metastases.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Encorafenib Triplet Could Address Poor Outcomes With Immunotherapy in BRAF V600–Mutant Melanoma With Brain Metastases @MoffittNews #Melanoma https://t.co/Cap8WXY5SL
-
-
Mashup Score: 6
The novel bispecific antibody TQB2930 plus chemotherapy elicited responses in heavily pretreated HER2-positive breast cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
The novel HER2-targeted bispecific antibody TQB2930 plus chemotherapy led to responses and displayed an acceptable safety profile in patients with HER2+ metastatic #BreastCancer who had received at least 2 prior HER2-targeted therapies. Read more: https://t.co/JcIPdYeBCt https://t.co/liGvf92QP3
-
-
Mashup Score: 3Isatuximab Plus VRd Approved in Europe for Transplant-Eligible Newly Diagnosed Multiple Myeloma - 12 hour(s) ago
The European Commission has approved isatuximab plus VRd in transplant-eligible newly diagnosed multiple myeloma.
Source: www.onclive.comCategories: General Medicine NewsTweet-
On July 25, the European Commission approved isatuximab-irfc plus bortezomib, lenalidomide, and dexamethasone as induction therapy for patients newly diagnosed with #MultipleMyeloma who are eligible for ASCT. Read here for more: https://t.co/rpeI42BnEE
-
-
Mashup Score: 3Inavolisib Plus Palbociclib/Fulvestrant Gains European Approval in PIK3CA-Mutant, HR+/HER2– Advanced Breast Cancer - 15 hour(s) ago
The European Commission has approved inavolisib plus palbociclib/fulvestrant in PIK3CA-mutant ER-positive, HER2-negative advanced breast cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Inavolisib plus palbociclib and fulvestrant has won European approval for patients with PIK3CA-mutant ER+, HER2–, locally advanced or metastatic #BreastCancer who had a recurrence after adjuvant endocrine therapy. #BCSM Read about the approval here: https://t.co/FdnZu35KG6 https://t.co/Nt5lPFGEBy
-
Phase 3 Evaluation of Sigvotatug Vedotin Is Underway in Pretreated Nonsquamous NSCLS @JyotiMalhotraMD @cityofhope #oncology #NSCLC #lcsm https://t.co/LdR8Ti94eE